Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Synthroid — THYRO-TABS
Application NDA021116 (NDA)
Tirosint — THYRO-TABS
Application NDA021116 (NDA)
Synthroid — SYNTHROID
Application NDA021402 (NDA)
Tirosint — SYNTHROID
Application NDA021402 (NDA)
Synthroid — LEVOLET
Application NDA021137 (NDA)
Tirosint — LEVOLET
Application NDA021137 (NDA)
Synthroid — TIROSINT
Application NDA021924 (NDA)
Tirosint — TIROSINT
Application NDA021924 (NDA)
Synthroid — LEVOTHYROXINE SODIUM
Application NDA202231 (NDA)
Tirosint — LEVOTHYROXINE SODIUM
Application NDA202231 (NDA)
Synthroid — TIROSINT-SOL
Application NDA206977 (NDA)
Tirosint — TIROSINT-SOL
Application NDA206977 (NDA)
Synthroid — LEVOTHYROXINE SODIUM
Application NDA210632 (NDA)
Tirosint — LEVOTHYROXINE SODIUM
Application NDA210632 (NDA)
Synthroid — THYQUIDITY
Application NDA214047 (NDA)
Tirosint — THYQUIDITY
Application NDA214047 (NDA)
Synthroid — LEVOTHYROXINE SODIUM
Application NDA214253 (NDA)
Tirosint — LEVOTHYROXINE SODIUM
Application NDA214253 (NDA)
Synthroid — ERMEZA
Application NDA215809 (NDA)
Tirosint — ERMEZA
Application NDA215809 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)